For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... providing a background level of blood glucose control ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...

Novo Nordisk A/S, et al., No. 25-cv-00713. Why was Novo Nordisk Sued for Securities Fraud? Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024 ... is not part of the valuation of the stock and has no bearing on financial results, unfortunately." ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy more ... The success of both Wegovy and Ozempic is due in no small part to the manufacturing expansion campaign Novo has been carrying ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...